🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 6 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 25/03/1993 | 4,13 | 4,13 | 3,75 | 4,13 | +6,45% | 9,09% | 45.200 |
| 24/03/1993 | 3,75 | 4,00 | 3,75 | 3,88 | +3,33% | 6,67% | 11.600 |
| 23/03/1993 | 3,75 | 4,13 | 3,75 | 3,75 | -3,23% | 10,00% | 99.600 |
| 22/03/1993 | 3,75 | 4,00 | 3,75 | 3,88 | +0,00% | 6,67% | 29.000 |
| 19/03/1993 | 4,13 | 4,13 | 3,88 | 3,88 | -4,62% | 6,06% | 55.600 |
| 18/03/1993 | 4,00 | 4,13 | 3,88 | 4,06 | +1,56% | 6,25% | 85.400 |
| 17/03/1993 | 4,00 | 4,00 | 3,75 | 4,00 | +0,00% | 6,25% | 134.200 |
| 16/03/1993 | 4,00 | 4,00 | 3,81 | 4,00 | +0,00% | 4,69% | 180.200 |
| 15/03/1993 | 3,75 | 4,00 | 3,75 | 4,00 | +3,23% | 6,67% | 800 |
| 12/03/1993 | 3,81 | 4,00 | 3,81 | 3,88 | +3,33% | 4,92% | 18.600 |
| 11/03/1993 | 4,00 | 4,00 | 3,75 | 3,75 | -6,25% | 6,25% | 9.600 |
| 10/03/1993 | 3,88 | 4,13 | 3,88 | 4,00 | +3,23% | 6,45% | 38.000 |
| 09/03/1993 | 4,00 | 4,25 | 3,88 | 3,88 | -6,06% | 9,38% | 18.400 |
| 08/03/1993 | 4,38 | 4,38 | 4,13 | 4,13 | -5,71% | 5,71% | 18.600 |
| 05/03/1993 | 4,13 | 4,38 | 4,13 | 4,38 | +2,94% | 6,06% | 5.400 |
| 04/03/1993 | 4,38 | 4,38 | 4,00 | 4,25 | +3,03% | 8,57% | 10.000 |
| 03/03/1993 | 4,13 | 4,38 | 3,88 | 4,13 | +6,45% | 12,12% | 140.600 |
| 02/03/1993 | 4,00 | 4,13 | 3,88 | 3,88 | -3,13% | 6,25% | 23.800 |
| 01/03/1993 | 3,88 | 4,00 | 3,63 | 4,00 | +6,67% | 9,68% | 155.400 |
| 26/02/1993 | 3,50 | 3,88 | 3,38 | 3,75 | +11,11% | 14,29% | 169.800 |
| 25/02/1993 | 3,50 | 3,50 | 3,25 | 3,38 | -3,57% | 7,14% | 123.600 |
| 24/02/1993 | 3,50 | 3,50 | 3,25 | 3,50 | +0,00% | 7,14% | 284.200 |
| 23/02/1993 | 3,75 | 3,88 | 3,31 | 3,50 | -12,50% | 15,00% | 114.400 |
| 22/02/1993 | 3,88 | 4,00 | 3,75 | 4,00 | -5,88% | 6,45% | 35.800 |
| 19/02/1993 | 4,06 | 4,25 | 3,88 | 4,25 | +6,25% | 9,23% | 19.800 |
| 18/02/1993 | 4,25 | 4,25 | 4,00 | 4,00 | +0,00% | 5,88% | 9.600 |
| 17/02/1993 | 4,00 | 4,00 | 4,00 | 4,00 | -5,88% | 0,00% | 3.200 |
| 16/02/1993 | 4,13 | 4,38 | 4,00 | 4,25 | -2,86% | 9,09% | 22.200 |
| 12/02/1993 | 4,50 | 4,50 | 4,13 | 4,38 | +0,00% | 8,33% | 24.200 |
| 11/02/1993 | 4,63 | 4,63 | 4,38 | 4,38 | -5,41% | 5,41% | 23.000 |